¶ Multi-Marker Pre-Symptomatic Screening and Adaptive Early Intervention Protocol
This therapeutic concept proposes a comprehensive biomarker screening and staged intervention protocol for identifying individuals in the pre-symptomatic/prodromal phase of neurodegenerative diseases. By combining genetic risk assessment with multi-modal biomarker panels, this approach enables personalized prevention strategies before irreversible neuronal loss occurs.
- Neurodegeneration begins decades before symptoms: Biomarker studies show amyloid accumulation begins 20-30 years before clinical AD; alpha-synuclein seeding detectable 10-15 years before PD
- Multiple biomarkers provide complementary information: Amyloid, tau, alpha-synuclein, NFL, and neurogranin each provide distinct prognostic information
- Staged intervention matches risk level: Prevention intensity can be matched to biomarker-defined risk level
- Early intervention maximizes efficacy: Disease-modifying therapies are most effective when pathology is minimal
flowchart TD
subgraph Screening_Phase
A["Genetic Testing<br/>APOE, GBA, LRRK2, SNCA"] --> B["Biomarker Panel<br/>Blood, CSF, Imaging"]
B --> C["Risk Stratification Score"]
end
subgraph Risk_Tiers
C --> D["Tier 1: High Risk<br/>Multiple positive biomarkers"]
C --> E["Tier 2: Moderate Risk<br/>Single biomarker positive"]
C --> F["Tier 3: Elevated Genetic Risk<br/>No biomarker changes"]
end
subgraph Intervention_Matching
D --> G["Intensive Protocol<br/>Combination therapy"]
E --> H["Targeted Monotherapy<br/>Pathology-specific"]
F --> I["Lifestyle + Monitoring<br/>Preventive measures"]
end
subgraph Longitudinal_Monitoring
G --> J["Quarterly Biomarker Review"]
H --> J
I --> J
J --> K["Adaptive Intervention Escalation"]
end
| Tier |
Criteria |
Age Range |
Intervention Intensity |
| Tier 1 |
Genetic risk + biomarker positive |
40-65 |
Intensive (combination therapy) |
| Tier 2 |
Single biomarker positive |
50-70 |
Moderate (targeted therapy) |
| Tier 3 |
Genetic risk only |
35-60 |
Lifestyle + monitoring |
- p-tau217: Highly specific for AD tau pathology, elevated in preclinical AD
- p-tau181: Alternative tau marker with good diagnostic performance
- NfL (Neurofilament Light): General neurodegeneration marker, elevated in pre-symptomatic PD/AD
- Alpha-synuclein seeds: RT-QuIC detects pre-clinical alpha-synuclein aggregation
- Amyloid-beta 42/40 ratio: Reduced ratio indicates cerebral amyloid accumulation
- Total tau and p-tau: Elevated in AD neurodegeneration
- Alpha-synuclein oligomers: Marker of synuclein pathology
- Amyloid PET: Quantifies cerebral amyloid burden (Centiloid scale)
- Tau PET: Maps tau neurofibrillary tangle distribution
- DaTscan: Assesses dopaminergic neuron integrity
- Anti-amyloid monoclonal antibody (lecanemab/donanemab)
- Lifestyle intervention bundle (diet, exercise, sleep)
- Monthly biomarker monitoring
- Pathology-specific monotherapy based on biomarker profile
- Quarterly biomarker monitoring
- Lifestyle intervention
- Semi-annual biomarker assessment
- Lifestyle intervention
- Risk factor modification
| Phase |
Design |
Population |
Primary Endpoint |
| II |
Prospective cohort |
At-risk individuals, age 40-70 |
Biomarker progression rate |
| III |
Randomized, adaptive |
Stratified by risk tier |
Time to clinical conversion |